Post-transplant lymphoproliferative disorder in paediatric patients: the Irish perspective-a single centre experience.

Abstract

Post-transplant lymphoproliferative disease (PTLD) is a serious complication of both solid organ and haematopoietic stem cell transplantation in children. Its incidence has increased over the last decade as a result of more potent immunosuppressive regimens. Many treatments have been explored however optimal therapy remains controversial. We report on the diagnosis, treatment and outcome of ten patients who were diagnosed with PTLD in Our Lady's Hospital for Sick Children in Dublin between 2004 and 2015 inclusive. Data were collected by retrospective review of patient medical records. 9 out of ten of our patients are alive and disease free following treatment for PTLD with rituximab alone or in combination with chemotherapy. The outcome of paediatric patients treated for PTLD at our institution is at least comparable to published international series and supports the use of rituximab±low dose chemotherapy in the treatment of this malignancy.